Coherus BioSciences (CHRS) Stock Forecast & Price Target

$1.52 +0.04 (+2.70%)

(As of 12/20/2024 05:31 PM ET)

Coherus BioSciences - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 4 Analyst Ratings

Sell
0

Hold
1

Buy
3

Based on 4 Wall Street analysts who have issued ratings for Coherus BioSciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 4 analysts, 1 has given a hold rating, and 3 have given a buy rating for CHRS.

Consensus Price Target

$5.38
253.62% Upside

According to the 4 analysts' twelve-month price targets for Coherus BioSciences, the average price target is $5.38. The highest price target for CHRS is $7.00, while the lowest price target for CHRS is $1.50. The average price target represents a forecasted upside of 253.62% from the current price of $1.52.

Get the Latest News and Ratings for CHRS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Coherus BioSciences and its competitors.

CHRS Analyst Ratings Over Time

Type	Current Forecast 12/22/23 to 12/21/24	1 Month Ago 11/22/23 to 11/21/24	3 Months Ago 9/23/23 to 9/22/24	1 Year Ago 12/22/22 to 12/22/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	3 Buy rating(s)	4 Buy rating(s)	6 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$5.38	$6.13	$6.92	$11.89
Forecasted Upside	253.62% Upside	454.30% Upside	578.10% Upside	488.56% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Did You See Trump’s Bombshell Exec. Order 001? (Ad)

Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."

I put all the details together for you here — but please hurry.

CHRS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CHRS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Coherus BioSciences Stock vs. The Competition

Type	Coherus BioSciences	Medical Companies	S&P 500
Consensus Rating Score	2.75	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	253.62% Upside	25,828.93% Upside	14.52% Upside
News Sentiment Rating	Positive News See Recent CHRS News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/5/2024	Robert W. Baird 2 of 5 stars		Boost Target	Outperform ➝ Outperform	$4.00 ➝ $6.00	+250.88%
12/4/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00	+309.35%
8/16/2024	UBS Group 4 of 5 stars	A. Verma Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$4.00 ➝ $1.50	-3.23%
5/13/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$8.00 ➝ $7.00	+258.97%
11/8/2023	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
10/23/2023	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$8.00 ➝ $7.00	+112.12%
Get the Latest News and Ratings for CHRS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Coherus BioSciences and its competitors with MarketBeat's FREE daily newsletter.
10/12/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$7.00 ➝ $6.00	+59.57%
7/24/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$12.00	+179.72%
3/14/2023	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$21.00 ➝ $23.00	+261.07%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 09:39 AM ET.

CHRS Forecast - Frequently Asked Questions

: According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for Coherus BioSciences is $5.38, with a high forecast of $7.00 and a low forecast of $1.50.
: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last twelve months. There is currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CHRS shares.
: According to analysts, Coherus BioSciences's stock has a predicted upside of 253.62% based on their 12-month stock forecasts.
: Coherus BioSciences has been rated by research analysts at HC Wainwright, and Robert W. Baird in the past 90 days.
: Analysts like Coherus BioSciences less than other "medical" companies. The consensus rating score for Coherus BioSciences is 2.75 while the average consensus rating score for "medical" companies is 2.81. Learn more on how CHRS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

AI breakthrough about to upend industry (Ad)

Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.

I urge you to watch it now.

This page (NASDAQ:CHRS) was last updated on 12/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Coherus BioSciences (CHRS) Stock Forecast & Price Target